Hypertrophic Cardiomyopathy
Conditions
Brief summary
This research study has been designed to test whether a drug called trientine dihydrochloride (also called Cufence) reduces heart muscle thickening, improves exercise capacity, improves heart function and reduces abnormal heart rhythms in patients with hypertrophic cardiomyopathy (HCM). The study is also assessing how trientine works in HCM. Participants will be prescribed either trientine or placebo, for a period of 12 months.
Detailed description
HCM is the most common inherited cardiovascular disorder. It is characterised by left ventricular (LV) myocardial hypertrophy and fibrosis. Patients can experience symptoms of effort intolerance, progressive heart failure and abnormal heart rhythms. There are currently no treatments that alter the natural history of HCM. Patients and the cardiovascular field have identified a critical need for clinical studies of drug therapies that target HCM pathophysiological mechanisms. Trientine dihydrochloride is a copper-chelating agent licensed for Wilson disease, a genetic disorder of copper excretion, in which patients exhibit a cardiac phenotype that mimics HCM. Proof of concept has been established through an MRC-funded study to suggest that use of trientine may also be beneficial in HCM.
Interventions
DRUGTrientine
Trientine dihydrochloride is a white to pale yellow crystalline hygroscopic powder.
DRUGPlacebo
Placebo capsule, manufactured with the exact components of the trientine capsules, without the active ingredient / investigational medicinal product.
Sponsors
National Institute for Health Research, United Kingdom
University of Manchester
University of Liverpool
Univar BV
University of Oxford
Manchester University NHS Foundation Trust
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Written informed consent. 2. Age 18-75 inclusive. 3. Hypertrophic cardiomyopathy (HCM), as defined by the European Society of Cardiology HCM guidelines as: a wall thickness ≥15 mm in one or more LV myocardial segments that is not explained solely by loading conditions. The same definition is applied to first-degree relatives of patients with HCM i.e. all participants are required to have a LV wall thickness ≥15 mm. Wall thickness is as measured on the most recent cardiovascular magnetic resonance (CMR) scan performed prior to the baseline visit. If CMR has not been performed previously, wall thickness measurement should be taken from the most recent echocardiogram performed prior to the baseline visit. (It is recognised that in the European Society of Cardiology guidelines a clinical diagnosis of HCM in first-degree relatives requires a wall thickness that is less than this value, however ≥15 mm is applied here in order to ensure that all participants have an unequivocal phenotype). 4. New York Heart Association class I, II or III at the most recent clinical assessment performed prior to the baseline visit.
Exclusion criteria
1. Previous or planned septal reduction therapy. 2. Previously documented myocardial infarction or severe coronary artery disease. 3. Uncontrolled hypertension, defined as a systolic blood pressure of \>180mmHg or a diastolic blood pressure of \> 100mmHg at Visit 1. 4. Known LV EF \< 50%, as measured on the most recent CMR scan performed prior to the baseline visit. If CMR has not been performed previously, the most recent echocardiogram performed prior to the baseline visit should be used. 5. Previously documented persistent atrial fibrillation. 6. Anaemia, defined as haemoglobin being below the local site normal reference range, at Visit 1. 7. Iron deficiency, defined as serum iron being below the local site normal reference range, at Visit 1. 8. Copper deficiency, defined as serum copper being below the normal reference range, at Visit 1. 9. Pacemaker or implantable cardioverter defibrillator. 10. Known severe valvular heart disease, as demonstrated on the most recent heart imaging performed prior to the baseline visit. 11. Previously documented other cardiomyopathic cause of myocardial hypertrophy (e.g. amyloidosis, Fabry disease, mitochondrial disease). 12. History of hypersensitivity to any of the components of the investigational medicinal product (IMP). 13. Known contraindication to MRI scanning. 14. Pregnancy, lactation or planning pregnancy. Women of childbearing capacity are required to have a negative serum pregnancy test before treatment, must agree to pregnancy tests at study visits as defined in the Section 8 and must agree to maintain highly effective contraception as defined in Section 8 during the study. 15. Any medical condition, which in the opinion of the Investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Left ventricular mass indexed to body surface area (LVMi) | 12 months | Change in LVMi (g/m2), measured using CMR, from baseline to week 52. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Exercise capacity | 12 months | Change in exercise capacity, measured using cardiopulmonary exercise testing (CPET), assessed from baseline to week 52. |
| Number of non-sinus supraventricular heart beats, presence and amount of atrial fibrillation, number of ventricular-origin beats and presence and amount of non-sustained ventricular tachycardia | 12 months | Change in number of non-sinus supraventricular heart beats, presence and amount of atrial fibrillation, number of ventricular-origin beats and presence and amount of non-sustained ventricular tachycardia, in 24 hours, measured using ambulatory heart monitoring, assessed from baseline to week 52. |
| Circulating high sensitivity troponin | 12 months | Change in circulating high sensitivity troponin, assessed from baseline to week 52. |
| LV global longitudinal strain, wall thickness, mass, volumes and ejection fraction (EF) | 12 months | Change in LV global longitudinal strain, wall thickness, mass, volumes and ejection fraction (EF) measured using CMR, assessed from baseline to week 52. |
| Peak left ventricular outflow | 12 months | Change in peak left ventricular outflow tract gradient, measured using CMR, assessed from baseline to week 52. |
| Atrial volume and function | 12 months | Change in atrial volume and function, measured using CMR, assessed from baseline to week 52. |
| Urine copper excretion | 12 months | Cumulative urine copper excretion, measured using urinary copper, assessed from baseline to weeks 13, 26, 39 and 52. |
Other
| Measure | Time frame | Description |
|---|---|---|
| LV myocardial extracellular volume | 12 months | Change in LV myocardial extracellular volume, measured using CMR, from baseline to week 52. |
| LV late gadolinium enhancement | 12 months | Change in LV late gadolinium enhancement, measured using CMR, from baseline to week 52. |
| PCr/ATP ratio | 12 months | Change in PCr/ATP ratio, measured using 31P MRS (sub-group), from baseline to week 52. |
| LV myocardial extracellular mass | 12 months | Change in LV myocardial extracellular mass, measured using CMR, from baseline to week 52. |
| LV myocardial cellular mass | 12 months | Change in LV myocardial cellular mass, measured using CMR, from baseline to week 52. |
Countries
United Kingdom
Outcome results
None listed